Eye on Congress

CQ Roll Call's Andrew Siddons reports on an 18-month House Oversight investigation that shows the extent to which drugmakers try to extend the profitable life of existing products rather than develop new ones and how price increases are more related to earnings reports and executive bonuses than research or rebates. Learn more about your ad choices. Visit megaphone.fm/adchoices